welcome
Investor's Business Daily

Investor's Business Daily

Health

Health

Moderna Stock Dives As Vaccine Troubles Rattle Its Topline

Investor's Business Daily
Summary
Nutrition label

87% Informative

Spikevax and mResvia missed first-quarter sales of messenger RNA -based vaccines.

In premarket trades, Moderna stock shed 5% , trading at 27.12 ; shares are trading well below their 50-day moving average.

The biotech company maintains its full-year outlook despite the first quarter sales miss.

It's important to note vaccine sales tend to spike in second half of the year .

VR Score

90

Informative language

90

Neutral language

71

Article tone

formal

Language

English

Language complexity

48

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

short-lived

Affiliate links

no affiliate links